Delving into the Latest Updates on Cellgram-LC with Synapse

Overview

Basic Info

Drug Type

Mesenchymal stem cell therapy

Synonyms

Autologous bone marrow-derived mesenchymal stem cell(Pharmicell)

Target-

Action-

Mechanism-

Therapeutic Areas-

Active Indication-

Inactive Indication-

Originator Organization

Pharmicell Co., Ltd.

Active Organization

Pharmicell Co., Ltd.

Inactive Organization-

License Organization-

Drug Highest PhasePhase 3

First Approval Date-

Regulation-

Login to view timeline

The goal of this clinical trial is to evaluate the efficacy and safety of Cellgram-LC in patients with alcoholic cirrhosis.
The main questions it aims to answer are:
* Is Cellgram-LC superior to best supportive care (BSC) in patients with alcoholic cirrhosis?
* What medical problems do participants have after receiving Cellgram-LC compared with BSC?
Participants will:
* Receive a single dose of Cellgram-LC at Week 0 or receive best supportive care according to their assigned study group.
* Attend clinic visits for scheduled assessments at Week 4 and Months 3, 6, 9, 12, 18, and 24.
* Complete scheduled telephone follow-up at Months 2, 4, 5, 7, 8, 10, 11, 15, 21, 27, 30, 33, and 36.
* Be followed for transplant-free survival and other study outcomes.

Start Date19 Apr 2021

Sponsor / Collaborator

Pharmicell Co., Ltd.

100 Clinical Results associated with Cellgram-LC

Login to view more data

100 Translational Medicine associated with Cellgram-LC

Login to view more data

100 Patents (Medical) associated with Cellgram-LC

Login to view more data

100 Deals associated with Cellgram-LC

Login to view more data